Malignant Peripheral Nerve Sheath Tumors: Latest Concepts in Disease Pathogenesis and Clinical Management

被引：39

作者：

Yao, Chengjun ^{[1
,2
]}

Zhou, Haiying ^{[1
]}

Dong, Yanzhao ^{[1
]}

Alhaskawi, Ahmad ^{[1
]}

Ezzi, Sohaib Hasan Abdullah ^{[3
,4
]}

Wang, Zewei ^{[1
,2
]}

Lai, Jingtian ^{[1
,2
]}

Kota, Vishnu Goutham ^{[3
]}

Abdulla, Mohamed Hasan Abdulla Hasan ^{[3
]}

Lu, Hui ^{[1
,5
]}

机构：

[1] Zhejiang Univ, Affiliated Hosp 1, Dept Orthoped, 79 Qingchun Rd, Hangzhou 310003, Peoples R China

[2] Zhejiang Univ, Sch Med, 866 Yuhangtang Rd, Hangzhou 310058, Peoples R China

[3] Zhejiang Univ, Affiliated Hosp 1, Dept Nucl Med, 79 Qingchun Rd, Hangzhou 310003, Peoples R China

[4] Cent South Univ, Xiangya Hosp 3, Dept Orthopaed, 138 Tongzipo Rd, Changsha 410013, Peoples R China

[5] Zhejiang Univ, Alibaba Zhejiang Univ Joint Res Ctr Future Digital, 866 Yuhangtang Rd, Hangzhou 310058, Peoples R China

来源：

CANCERS | 2023年 / 15卷 / 04期

关键词：

malignant peripheral nerve sheath tumor; neurofibromatosis type 1; plexiform neurofibroma; atypical neurofibromatous neoplasm of unknown biological potential; molecular diagnosis; target therapy; POSITRON-EMISSION-TOMOGRAPHY; FINE-NEEDLE-ASPIRATION; SOFT-TISSUE SARCOMAS; NEUROFIBROMATOSIS TYPE-1; PLEXIFORM NEUROFIBROMAS; PHASE-II; RADIATION-THERAPY; SIGNALING PATHWAY; RAPAMYCIN PATHWAY; MAMMALIAN TARGET;

D O I：

10.3390/cancers15041077

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Simple Summary Malignant peripheral nerve sheath tumor (MPNST) is a soft tissue sarcoma with limited therapeutic interventions and a poor prognosis. This review summarized the current understanding of the pathogenic mechanisms behind MPNST and the latest concepts in clinical management from diagnosis to therapeutic intervention. Additionally, the developments in molecular diagnosis and targeted therapies for MPNST are highlighted. It concluded with the challenges and prospects of MPNST management. Malignant peripheral nerve sheath tumor (MPNST) is an aggressive soft tissue sarcoma with limited therapeutic options and a poor prognosis. Although neurofibromatosis type 1 (NF1) and radiation exposure have been identified as risk factors for MPNST, the genetic and molecular mechanisms underlying MPNST pathogenesis have only lately been roughly elucidated. Plexiform neurofibroma (PN) and atypical neurofibromatous neoplasm of unknown biological potential (ANNUBP) are novel concepts of MPNST precancerous lesions, which revealed sequential mutations in MPNST development. This review summarized the current understanding of MPNST and the latest consensus from its diagnosis to treatment, with highlights on molecular biomarkers and targeted therapies. Additionally, we discussed the current challenges and prospects for MPNST management.

引用

页数：19

共 133 条

[1]

Albritton KH, 2006, J CLIN ONCOL, V24, p524S

[2]

Amanullah A, 2022, J NUCL MED, V63

[3] Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells [J].

Ambrosini, Grazia ;

Cheema, Haider S. ;

Seelman, Sharon ;

Teed, Allison ;

Sambol, Elliot B. ;

Singer, Samuel ;

Schwartz, Gary K. .

MOLECULAR CANCER THERAPEUTICS, 2008, 7 (04) :890-896

[4]

Anderson Jacqueline L, 2015, Handb Clin Neurol, V132, P75, DOI 10.1016/B978-0-444-62702-5.00004-4

[5] Malignant peripheral nerve sheath tumor - The clinical spectrum and outcome of treatment [J].

Baehring, JM ;

Betensky, RA ;

Batchelor, TT .

NEUROLOGY, 2003, 61 (05) :696-698

[6] Combined PET/MR: The Real Work Has Just Started. Summary Report of the Third International Workshop on PET/MR Imaging; February 17-21, 2014, Tubingen, Germany [J].

Bailey, D. L. ;

Antoch, G. ;

Bartenstein, P. ;

Barthel, H. ;

Beer, A. J. ;

Bisdas, S. ;

Bluemke, D. A. ;

Boellaard, R. ;

Claussen, C. D. ;

Franzius, C. ;

Hacker, M. ;

Hricak, H. ;

la Fougere, C. ;

Gueckel, B. ;

Nekolla, S. G. ;

Pichler, B. J. ;

Purz, S. ;

Quick, H. H. ;

Sabri, O. ;

Sattler, B. ;

Schaefer, J. ;

Schmidt, H. ;

van den Hoff, J. ;

Voss, S. ;

Weber, W. ;

Wehrl, H. F. ;

Beyer, T. .

MOLECULAR IMAGING AND BIOLOGY, 2015, 17 (03) :297-312

[7] ABERRANT REGULATION OF RAS PROTEINS IN MALIGNANT-TUMOR CELLS FROM TYPE-1 NEUROFIBROMATOSIS PATIENTS [J].

BASU, TN ;

GUTMANN, DH ;

FLETCHER, JA ;

GLOVER, TW ;

COLLINS, FS ;

DOWNWARD, J .

NATURE, 1992, 356 (6371) :713-715

[8] Quantitative F18-Fluorodeoxyglucose Positron Emission Tomography Accurately Characterizes Peripheral Nerve Sheath Tumors as Malignant or Benign [J].

Benz, Matthias R. ;

Czernin, Johannes ;

Dry, Sarah M. ;

Tap, William D. ;

Allen-Auerbach, Martin S. ;

Elashoff, David ;

Phelps, Michael E. ;

Weber, Wolfgang A. ;

Eilber, Fritz C. .

CANCER, 2010, 116 (02) :451-458

[9] Vemurafenib: the first drug approved for BRAF-mutant cancer [J].

Bollag, Gideon ;

Tsai, James ;

Zhang, Jiazhong ;

Zhang, Chao ;

Ibrahim, Prabha ;

Nolop, Keith ;

Hirth, Peter .

NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (11) :873-886

[10] Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours [J].

Bottillo, Irene ;

Ahiquist, Terje ;

Brekke, Helge ;

Danielsen, Stine A. ;

van den Berg, Eva ;

Mertens, Fredrik ;

Lothe, Ragnhild A. ;

Dallapiccola, Bruno .

JOURNAL OF PATHOLOGY, 2009, 217 (05) :693-701

← 1 2 3 4 5 6 7 8 9 10 →